Moore M, Taylor G M, White W J
Cancer Immunol Immunother. 1982;13(1):56-61. doi: 10.1007/BF00200202.
Twenty-two human leukaemias, comprising acute phase leucocytes from 13 acute myeloid and nine lymphoid leukaemias, were tested for susceptibility to spontaneous cell-mediated cytotoxicity (CMC) by untreated lymphocytes and lymphocytes treated for 18 h with 250 IU lymphoblastoid (Namalva) interferon (IFN-alpha). IFN-amplified killing (IAK) by lymphocytes from 24 normal lymphocyte donors was checked on the K562 erythroleukaemia cell line, for comparison with IAK on fresh leukaemias. Nine leukaemias were tested with lymphocytes from three donors, nine with lymphocytes from six donors, three with lymphocytes from nine donors, and one with lymphocytes from 11 donors. Some degree of susceptibility to IAK was found in five acute myeloid and five lymphoid leukaemias, which was markedly dependent upon the source of the effector lymphocytes and did not correlate with the degree of IAK on K562. The 12 other leukaemias were virtually resistant to IAK. The results emphasize the variability in the capacity of IFN-treated lymphocytes to lyse leukaemias that have not been adapted to tissue culture. The basis of effector recognition of cell line and fresh tumour targets is discussed.
对22例人类白血病进行了检测,这些白血病包括来自13例急性髓系白血病和9例淋巴细胞白血病的急性期白细胞,检测其对未经处理的淋巴细胞以及用250国际单位淋巴母细胞样(Namalva)干扰素(IFN-α)处理18小时的淋巴细胞的自发细胞介导细胞毒性(CMC)的敏感性。检测了来自24名正常淋巴细胞供体的淋巴细胞对K562红白血病细胞系的IFN增强杀伤作用(IAK),以与对新鲜白血病细胞的IAK作用进行比较。对9例白血病用来自3名供体的淋巴细胞进行检测,9例用来自6名供体的淋巴细胞检测,3例用来自9名供体的淋巴细胞检测,1例用来自11名供体的淋巴细胞检测。在5例急性髓系白血病和5例淋巴细胞白血病中发现了一定程度的对IAK的敏感性,这明显取决于效应淋巴细胞的来源,并且与对K562细胞的IAK程度无关。其他12例白血病实际上对IAK有抗性。结果强调了经IFN处理的淋巴细胞裂解未适应组织培养的白血病细胞的能力存在变异性。讨论了效应细胞对细胞系和新鲜肿瘤靶标的识别基础。